Literature DB >> 11836670

Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.

Paul Baas1.   

Abstract

It has been a challenge to find effective chemotherapeutic treatments for malignant mesothelioma. Over the last several decades numerous single-drug and combination regimens have been examined, but no standard treatment with chemotherapy alone has emerged. Possible explanations for this lack of success are the heterogeneity between the different subclasses of mesothelioma and the difficulties experienced in determining responses on computed tomographic (CT) scan. This review will present the results of most chemotherapy trials. An attempt is also been made to overcome the problem of identifying the overall response rate by presenting the median survival time. Other types of response evaluation and guidelines for patient selection are warranted to properly compare chemotherapeutic treatments. Copyright 2002 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836670     DOI: 10.1053/sonc.2002.30231

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

1.  Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.

Authors:  Zhiwen Liu; Julius Klominek
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

Review 2.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register.

Authors:  V Neumann; A Rütten; M Scharmach; K-M Müller; M Fischer
Journal:  Int Arch Occup Environ Health       Date:  2004-02-27       Impact factor: 3.015

4.  Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.

Authors:  Anne S Tsao; Nusrat Harun; J Jack Lee; John Heymach; Katherine Pisters; Waun Ki Hong; Junya Fujimoto; Ignacio Wistuba
Journal:  Clin Lung Cancer       Date:  2013-12-27       Impact factor: 4.785

5.  An epigenetic mechanism for capecitabine resistance in mesothelioma.

Authors:  K V Kosuri; X Wu; L Wang; M A Villalona-Calero; G A Otterson
Journal:  Biochem Biophys Res Commun       Date:  2009-12-24       Impact factor: 3.575

Review 6.  Current therapy for malignant mesothelioma.

Authors:  W Roy Smythe
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.945

7.  Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents.

Authors:  Elham Alizadeh Pasdar; Michael Smits; Michael Stapelberg; Martina Bajzikova; Marina Stantic; Jacob Goodwin; Bing Yan; Jan Stursa; Jaromira Kovarova; Karishma Sachaphibulkij; Ayenachew Bezawork-Geleta; Margaryta Sobol; Anatoly Filimonenko; Marco Tomasetti; Renata Zobalova; Pavel Hozak; Lan-Feng Dong; Jiri Neuzil
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

Review 8.  Advances in the management of malignant mesothelioma.

Authors:  Mazen Y Khalil; Marissa Mapa; Hyung Ju C Shin; Dong M Shin
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.945

9.  The cytotoxic effect of magainin II on the MDA-MB-231 and M14K tumour cell lines.

Authors:  Radu Anghel; Daniela Jitaru; Laurenţiu Bădescu; Magda Bădescu; Manuela Ciocoiu
Journal:  Biomed Res Int       Date:  2013-10-09       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.